Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Decibel Therapeutics, Inc. (DBTX : NSDQ)
 
 • Company Description   
Decibel Therapeutics is a clinical-stage biotechnology company. It engages in discovering and developing transformative treatments to restore and improve hearing and balance. Decibel Therapeutics is based in BOSTON.

Number of Employees: 62

 
 • Price / Volume Information   
Yesterday's Closing Price: $2.32 Daily Weekly Monthly
20 Day Moving Average: 71,295 shares
Shares Outstanding: 24.97 (millions)
Market Capitalization: $57.92 (millions)
Beta: 0.45
52 Week High: $9.75
52 Week Low: $1.84
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 1.75% 14.61%
12 Week -35.56% -29.15%
Year To Date -50.11% -39.04%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
1325 Boylston Street Suite 500
-
Boston,MA 02215
USA
ph: 617-370-8701
fax: -
ir@decibeltx.com None
 
 • General Corporate Information   
Officers
Laurence Reid - Chief Executive Officer; President and Director
William H. Carson - Chairman
Elisabeth Leiderman - Chief Financial Officer
Neil Exter - Director
Alison Finger - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 24343R106
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/09/22
Share - Related Items
Shares Outstanding: 24.97
Most Recent Split Date: (:1)
Beta: 0.45
Market Capitalization: $57.92 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.54 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-1.68 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/09/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 0.45
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: 48.62%
vs. Previous Quarter: -14.29%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/22 - -37.06
12/31/21 - -32.11
09/30/21 - -46.15
ROA
03/31/22 - -29.69
12/31/21 - -26.79
09/30/21 - -31.56
Current Ratio
03/31/22 - 8.35
12/31/21 - 7.99
09/30/21 - 9.08
Quick Ratio
03/31/22 - 8.35
12/31/21 - 7.99
09/30/21 - 9.08
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Book Value
03/31/22 - 5.13
12/31/21 - 5.68
09/30/21 - 6.19
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©